Zhangzhou Pientzehuang Pharmaceutical (600436) Q3 2026 earnings summary

Executive summary

• Q3 revenue fell 13.91% YoY to RMB 1,776,652,151.62; net profit attributable to shareholders declined 71.67% to RMB 194,666,741.82.

• 9M revenue decreased 14.68% YoY to RMB 6,349,495,773.18 and attributable net profit fell 39.53% to RMB 1,287,640,802.17.

• Management attributed lower earnings to reduced pharmaceutical-industry profits and lower investment income at a subsidiary; 9M operating cash flow rose 376.05% to RMB 2,317,134,900.58.

Financial highlights

• Q3 total profit was RMB 164,842,808.01, down 78.85% YoY; 9M total profit was RMB 1,453,452,092.53, down 41.51%.

• Adjusted for non-recurring items, attributable net profit was RMB 250,890,181.94 in Q3, down 42.69%, and RMB 1,305,476,785.23 for 9M, down 30.95%.

• 9M basic and diluted EPS were both RMB 2.13, down 39.66%; Q3 EPS was RMB 0.32, down 71.93%.

• 9M operating revenue declined while operating costs fell to RMB 4,921,805,070.77 from RMB 5,323,980,740.23 YoY.

Segment performance

• Pharmaceutical-industry profits declined, contributing to lower reported and adjusted earnings; no segment-level revenue breakdown is included in the reported figures.